SSID Group said that the assets acquired in the deal will complement its gastric health portfolio and let it offer a broader range of tests to US labs.

Roche confirmed its full-year outlook with sales expected to increase in the mid-single-digit percent range at constant exchange rates. The firm added that EPS for full-year 2025 is expected to ...

A number of the Dutch firm's products have received certification under Europe's In Vitro Diagnostic Regulation recently.